

W Marston Linehan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1429121/publications.pdf>

Version: 2024-02-01

323
papers

40,210
citations

2543

96
h-index

2680

193
g-index

332
all docs

332
docs citations

332
times ranked

28199
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of the von Hippel-Lindau disease tumor suppressor gene. <i>Science</i> , 1993, 260, 1317-1320.	6.0	2,723
2	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. <i>Nature Genetics</i> , 1997, 16, 68-73.	9.4	1,461
3	von Hippel-Lindau disease. <i>Lancet, The</i> , 2003, 361, 2059-2067.	6.3	1,322
4	Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 390.	3.8	1,267
5	Reductive carboxylation supports growth in tumour cells with defective mitochondria. <i>Nature</i> , 2012, 481, 385-388.	13.7	1,074
6	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
7	Biochemical Diagnosis of Pheochromocytoma. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1427-34.	3.8	994
8	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. <i>Cancer Cell</i> , 2005, 8, 143-153.	7.7	843
9	Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. <i>Cancer Cell</i> , 2002, 2, 157-164.	7.7	833
10	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	7.7	665
11	The genetic basis of kidney cancer: a metabolic disease. <i>Nature Reviews Urology</i> , 2010, 7, 277-285.	1.9	634
12	Mutations in the Fumarate Hydratase Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North America. <i>American Journal of Human Genetics</i> , 2003, 73, 95-106.	2.6	563
13	Renal Tumors in the Birt-Hogg-Dubé Syndrome. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1542-1552.	2.1	544
14	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. <i>Human Mutation</i> , 1995, 5, 66-75.	1.1	526
15	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
16	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2001, 134, 315.	2.0	512
17	Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 4726-4734.	3.2	503
18	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. <i>Oncogene</i> , 1999, 18, 2343-2350.	2.6	487

#	ARTICLE	IF	CITATIONS
19	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. <i>Human Mutation</i> , 1998, 12, 417-423.	1.1	452
20	The Genetic Basis of Cancer of the Kidney. <i>Journal of Urology</i> , 2003, 170, 2163-2172.	0.2	447
21	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. <i>Human Mutation</i> , 1996, 8, 348-357.	1.1	436
22	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019, 179, 964-983.e31.	13.5	430
23	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15552-15557.	3.3	427
24	The contribution of VHL substrate binding and HIF1-1 α to the phenotype of VHL loss in renal cell carcinoma. <i>Cancer Cell</i> , 2002, 1, 247-255.	7.7	421
25	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 181-186.	0.8	401
26	Germline BHD-Mutation Spectrum and Phenotype Analysis of a Large Cohort of Families with Birt-Hogg-Dub \AA Syndrome. <i>American Journal of Human Genetics</i> , 2005, 76, 1023-1033.	2.6	363
27	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. <i>Nature Reviews Urology</i> , 2019, 16, 539-552.	1.9	357
28	Birt-Hogg-Dub \AA Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. <i>American Journal of Human Genetics</i> , 2001, 69, 876-882.	2.6	355
29	Lung Cysts, Spontaneous Pneumothorax, and Genetic Associations in 89 Families with Birt-Hogg-Dub \AA Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1044-1053.	2.5	318
30	High Frequency ofSDHGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4505-4509.	1.8	299
31	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. <i>Oncogene</i> , 1997, 15, 2233-2239.	2.6	298
32	Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. <i>Nature Genetics</i> , 1998, 20, 66-69.	9.4	291
33	Hereditary Papillary Renal Cell Carcinoma. <i>Journal of Urology</i> , 1994, 151, 561-566.	0.2	289
34	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. <i>Clinical Chemistry</i> , 2011, 57, 411-420.	1.5	282
35	Oxidation of Alpha-Ketoglutarate Is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects. <i>Cell Reports</i> , 2014, 7, 1679-1690.	2.9	281
36	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1999-2008.	1.8	262

#	ARTICLE	IF	CITATIONS
37	EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÉ SYNDROME. <i>Journal of Urology</i> , 2005, 173, 1482-1486.	0.2	260
38	Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. <i>Familial Cancer</i> , 2014, 13, 637-644.	0.9	251
39	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. <i>Electrophoresis</i> , 2000, 21, 2235-2242.	1.3	246
40	Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. <i>American Journal of Pathology</i> , 1998, 153, 223-231.	1.9	243
41	Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. <i>American Journal of Pathology</i> , 1999, 155, 517-526.	1.9	243
42	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. <i>Journal of Urology</i> , 2007, 177, 2074-2080.	0.2	235
43	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. <i>Journal of Urology</i> , 1999, 162, 659-664.	0.2	233
44	Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). <i>Surgery</i> , 2007, 142, 814-818.e2.	1.0	232
45	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. <i>Journal of Urology</i> , 1999, 161, 1475-1479.	0.2	229
46	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. <i>Journal of Urology</i> , 2012, 188, 2152-2157.	0.2	227
47	Molecular genetics and cellular features of TFE3 and TFE3 fusion kidney cancers. <i>Nature Reviews Urology</i> , 2014, 11, 465-475.	1.9	227
48	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. <i>Journal of the National Cancer Institute</i> , 2008, 100, 140-154.	3.0	223
49	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dubé Associated Renal Tumors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 931-935.	3.0	213
50	Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1 α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. <i>Molecular and Cellular Biology</i> , 2009, 29, 4080-4090.	1.1	212
51	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. <i>Journal of Urology</i> , 2012, 188, 2063-2071.	0.2	211
52	Hereditary Renal Cancers. <i>Radiology</i> , 2003, 226, 33-46.	3.6	210
53	Robotic Partial Nephrectomy for Complex Renal Tumors: Surgical Technique. <i>European Urology</i> , 2008, 53, 514-523.	0.9	210
54	Homozygous loss of <i>BHD</i> causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18722-18727.	3.3	203

#	ARTICLE	IF	CITATIONS
55	Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. <i>Genome Research</i> , 2012, 22, 2089-2100.	2.4	202
56	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. <i>Journal of Urology</i> , 2001, 165, 777-781.	0.2	198
57	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. <i>Cancer Cell</i> , 2011, 20, 315-327.	7.7	190
58	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. <i>Journal of Urology</i> , 2012, 188, 1157-1163.	0.2	188
59	Genetic Basis of Cancer of the Kidney. <i>Clinical Cancer Research</i> , 2004, 10, 6282S-6289S.	3.2	187
60	THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE. <i>Journal of Urology</i> , 2004, 172, 63-65.	0.2	181
61	Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies. <i>Oncologist</i> , 2012, 17, 46-54.	1.9	177
62	Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-DubÃ© syndrome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 393-400.	1.1	177
63	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. <i>Journal of Urology</i> , 1995, 153, 907-912.	0.2	176
64	Molecular genetics and clinical features of Birtâ€™Hoggâ€™DubÃ© syndrome. <i>Nature Reviews Urology</i> , 2015, 12, 558-569.	1.9	175
65	Molecular Pathways: <i>Fumarate Hydratase</i> -Deficient Kidney Cancerâ€™Targeting the Warburg Effect in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3345-3352.	3.2	172
66	Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. <i>Journal of Urology</i> , 1995, 154, 2010-2015.	0.2	170
67	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2010, 18, 97-111.	1.6	169
68	Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors. <i>PLoS Genetics</i> , 2011, 7, e1002312.	1.5	168
69	Identification and characterization of a novel folliculin-interacting protein FNIP2. <i>Gene</i> , 2008, 415, 60-67.	1.0	163
70	The Metabolic Basis of Kidney Cancer. <i>Cancer Discovery</i> , 2019, 9, 1006-1021.	7.7	163
71	LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 68-72.	0.2	159
72	Molecular Diagnosis and Therapy of Kidney Cancer. <i>Annual Review of Medicine</i> , 2010, 61, 329-343.	5.0	154

#	ARTICLE	IF	CITATIONS
73	Robotic Partial Nephrectomy for Renal Hilar Tumors: A Multi-Institutional Analysis. <i>Journal of Urology</i> , 2008, 180, 2353-2356.	0.2	147
74	Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. <i>PLoS ONE</i> , 2010, 5, e15793.	1.1	146
75	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. <i>Drug Development Research</i> , 2000, 49, 34-42.	1.4	144
76	Characterization of the Renal Pathology of a Familial Form of Renal Cell Carcinoma Associated With Von Hippel-Lindau Disease: Clinical and Molecular Genetic Implications. <i>Journal of Urology</i> , 1995, 153, 22-26.	0.2	143
77	A Novel Germline Mutation in <i>BAP1</i> Predisposes to Familial Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2013, 11, 1061-1071.	1.5	135
78	Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 431-437.	0.8	135
79	FLCN : The causative gene for Birt-Hogg-Dubé syndrome. <i>Gene</i> , 2018, 640, 28-42.	1.0	133
80	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. <i>Journal of Urology</i> , 1993, 150, 463-466.	0.2	132
81	The metabolic basis of kidney cancer. <i>Seminars in Cancer Biology</i> , 2013, 23, 46-55.	4.3	132
82	Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2007, 13, 671s-679s.	3.2	131
83	UOK 262 cell line, fumarate hydratase deficient (FH ^{-/-} /FH ^{-/-}) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 45-55.	1.0	131
84	FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. <i>Journal of Urology</i> , 1998, 160, 335-340.	0.2	127
85	Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. <i>Modern Pathology</i> , 2004, 17, 998-1011.	2.9	124
86	CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1997, 158, 1675-1678.	0.2	120
87	Focus on kidney cancer. <i>Cancer Cell</i> , 2004, 6, 223-228.	7.7	119
88	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. <i>Journal of Urology</i> , 2004, 172, 1256-1261.	0.2	115
89	Hereditary leiomyomatosis and renal cell carcinoma. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 253.	0.8	112
90	Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 757-766.	2.1	111

#	ARTICLE	IF	CITATIONS
91	Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. <i>Oncogene</i> , 1999, 18, 1205-1208.	2.6	108
92	Genetic predisposition to kidney cancer. <i>Seminars in Oncology</i> , 2016, 43, 566-574.	0.8	107
93	INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. <i>Journal of Urology</i> , 1999, 162, 43-45.	0.2	102
94	Surgical Management of Pheochromocytoma with the Use of Metyrosine. <i>Annals of Surgery</i> , 1990, 212, 621-628.	2.1	101
95	Hereditary kidney cancer. <i>Cancer</i> , 2009, 115, 2252-2261.	2.0	101
96	Translocation Renal Cell Carcinomas in Adults. <i>American Journal of Surgical Pathology</i> , 2012, 36, 654-662.	2.1	98
97	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. <i>Journal of Urology</i> , 1999, 161, 395-398.	0.2	97
98	Epididymal cystadenomas in von Hippel-Lindau disease. <i>Urology</i> , 1997, 49, 926-931.	0.5	96
99	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv287.	3.0	92
100	PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. <i>Journal of Urology</i> , 2000, 163, 431-433.	0.2	91
101	Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1122-1131.	3.6	91
102	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. <i>Journal of Urology</i> , 1990, 144, 614-617.	0.2	90
103	Partial adrenalectomy: The National Cancer Institute experience. <i>Urology</i> , 2005, 66, 19-23.	0.5	89
104	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. <i>Clinical Cancer Research</i> , 2015, 21, 10-17.	3.2	88
105	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. <i>Journal of Urology</i> , 1995, 153, 913-916.	0.2	87
106	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. <i>Cancer Cell</i> , 2014, 26, 840-850.	7.7	87
107	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. <i>Cancer Research</i> , 2016, 76, 2177-2185.	0.4	86
108	Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. <i>Human Mutation</i> , 2004, 23, 40-46.	1.1	85

#	ARTICLE	IF	CITATIONS
109	Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer. <i>Journal of Urology</i> , 2013, 190, 1990-1998.	0.2	85
110	Diagnosis and management of BHD-associated kidney cancer. <i>Familial Cancer</i> , 2013, 12, 397-402.	0.9	85
111	Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. <i>Cell Reports</i> , 2014, 7, 412-423.	2.9	84
112	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
113	Endolymphatic sac tumors in von Hippel-Lindau disease. <i>Journal of Neurosurgery</i> , 2004, 100, 480-487.	0.9	83
114	Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. <i>Journal of Urology</i> , 2008, 179, 67-70.	0.2	83
115	Association of Germline Mutations in the Fumarate Hydratase Gene and Uterine Fibroids in Women With Hereditary Leiomyomatosis and Renal Cell Cancer. <i>Archives of Dermatology</i> , 2008, 144, 1584-92.	1.7	83
116	Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1750-1764.	3.0	82
117	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF- β signaling. <i>Molecular Cancer</i> , 2010, 9, 160.	7.9	81
118	Development of a prostate cDNA microarray and statistical gene expression analysis package. , 2000, 28, 12-22.		80
119	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	0.9	80
120	Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. <i>PLoS ONE</i> , 2013, 8, e72179.	1.1	80
121	EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. <i>Journal of Urology</i> , 2001, 165, 1329-1334.	0.2	79
122	Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. <i>Cell Chemical Biology</i> , 2017, 24, 231-242.	2.5	79
123	ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondria. <i>Oncotarget</i> , 2018, 9, 18454-18479.	0.8	77
124	A chemoproteomic portrait of the oncometabolite fumarate. <i>Nature Chemical Biology</i> , 2019, 15, 391-400.	3.9	77
125	Englerin A Stimulates PKC ζ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality. <i>Cancer Cell</i> , 2013, 23, 228-237.	7.7	74
126	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1624-31.	3.3	74

#	ARTICLE	IF	CITATIONS
127	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. <i>Cell Reports</i> , 2020, 30, 1798-1810.e4.	2.9	73
128	Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. <i>Science</i> , 2021, 373, 236-241.	6.0	71
129	Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomas. <i>JAMA Ophthalmology</i> , 2007, 125, 239.	2.6	70
130	Acute loss of iron-sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 8297-8311.	1.6	70
131	Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2011, 2, 515-526.	1.2	69
132	Studying Cancer Families to Identify Kidney Cancer Genes. <i>Annual Review of Medicine</i> , 2003, 54, 217-233.	5.0	66
133	Targeting the Met signaling pathway in renal cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 785-793.	1.1	66
134	Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. <i>Journal of Urology</i> , 2009, 182, 1280-1286.	0.2	66
135	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. <i>Journal of Urology</i> , 2010, 184, 1855-1859.	0.2	66
136	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 787-797.	3.3	64
137	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. <i>Science Signaling</i> , 2021, 14, .	1.6	64
138	Imaging Features of Hereditary Papillary Renal Cancers. <i>Journal of Computer Assisted Tomography</i> , 1997, 21, 737-741.	0.5	63
139	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. <i>European Urology</i> , 2013, 63, 244-251.	0.9	61
140	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
141	Robot-Assisted Laparoscopic Partial Adrenalectomy for Pheochromocytoma: The National Cancer Institute Technique. <i>European Urology</i> , 2011, 60, 118-124.	0.9	58
142	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5977-5989.	3.2	58
143	Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. <i>PLoS ONE</i> , 2014, 9, e85621.	1.1	58
144	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dub syndrome is required for murine B-cell development. <i>Blood</i> , 2012, 120, 1254-1261.	0.6	57

#	ARTICLE	IF	CITATIONS
145	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. <i>Nature Communications</i> , 2016, 7, 12037.	5.8	56
146	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). <i>PLoS ONE</i> , 2015, 10, e0140257.	1.1	56
147	The UOK 257 cell line: a novel model for studies of the human Birtâ€™Hoggâ€™DubÃ© gene pathway. <i>Cancer Genetics and Cytogenetics</i> , 2008, 180, 100-109.	1.0	55
148	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. <i>Cancer Genetics</i> , 2012, 205, 377-390.	0.2	55
149	MicroRNAâ€™204â€™5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 1897-1908.	1.7	55
150	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. <i>Human Molecular Genetics</i> , 2014, 23, 5706-5719.	1.4	54
151	Differential expression of the mismatch repair gene MSH2 in malignant prostate tissue is associated with cancer recurrence. <i>Cancer</i> , 2002, 94, 690-699.	2.0	53
152	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5004-5004.	0.8	53
153	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 779-790.	1.4	51
154	Identification of intragenic deletions and duplication in the <i>FLCN</i> gene in Birtâ€™Hoggâ€™DubÃ© syndrome. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 466-477.	1.5	50
155	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 753-756.	1.2	49
156	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 151-156.	1.5	48
157	Management of von Hippelâ€™Lindau-associated kidney cancer. <i>Nature Reviews Urology</i> , 2005, 2, 248-255.	1.4	48
158	Robot-assisted Laparoscopic Partial Adrenalectomy: Initial Experience. <i>Urology</i> , 2011, 77, 775-780.	0.5	47
159	Evaluation of Color Doppler Intraoperative Ultrasound in Parenchymal Sparing Renal Surgery. <i>Journal of Urology</i> , 1994, 152, 1984-1987.	0.2	44
160	Intratumoral heterogeneity in kidney cancer. <i>Nature Genetics</i> , 2014, 46, 214-215.	9.4	44
161	Association of <i>VHL</i> Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippelâ€™Lindau Disease. <i>JAMA Oncology</i> , 2018, 4, 124.	3.4	44
162	The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. <i>BJU International</i> , 2005, 95, 2-7.	1.3	43

#	ARTICLE	IF	CITATIONS
163	Clinical features, genetics and potential therapeutic approaches for Birtâ€“Hoggâ€“DubÃ© syndrome. Expert Opinion on Orphan Drugs, 2015, 3, 15-29.	0.5	43
164	Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. Journal of Clinical Oncology, 2018, 36, 3540-3546.	0.8	41
165	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40
166	Phase II study of the oral HIF-2Î± inhibitor MK-6482 for Von Hippel-Lindau diseaseâ€“associated renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5003-5003.	0.8	40
167	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	0.8	39
168	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Reports, 2019, 26, 1344-1356.e5.	2.9	38
169	Improved detection of germline mutations in the von Hippelâ€“Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	1.1	38
170	Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. Journal of Neurosurgery, 2016, 124, 971-976.	0.9	37
171	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Cell, 2018, 173, 540-542.	13.5	37
172	Non-Clear Cell Renal Cancer: Disease-Based Management and Opportunities for Targeted Therapeutic Approaches. Seminars in Oncology, 2013, 40, 511-520.	0.8	36
173	Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 42-49.	3.2	36
174	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	0.9	36
175	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	7.7	35
176	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118.	1.0	35
177	Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733.	0.8	35
178	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. Molecular Cancer Research, 2019, 17, 1613-1626.	1.5	35
179	Germline mutations in the Von Hippelâ€“Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	1.1	33
180	Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes and Cancer, 1994, 11, 15-20.	1.5	32

#	ARTICLE	IF	CITATIONS
181	Targeted therapies for non-clear renal cell carcinoma. <i>Targeted Oncology</i> , 2010, 5, 119-129.	1.7	32
182	A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. <i>Journal of Urology</i> , 1991, 145, 1040-1042.	0.2	31
183	Kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 948-951.	0.8	31
184	Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 23.e9-23.e13.	0.8	30
185	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. <i>Journal of Translational Medicine</i> , 2010, 8, 8.	1.8	29
186	Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. <i>American Journal of Human Genetics</i> , 2018, 103, 358-366.	2.6	29
187	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. <i>Blood</i> , 2021, 137, 126-137.	0.6	29
188	Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. <i>JAMA Dermatology</i> , 2015, 151, 770.	2.0	28
189	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. <i>Cancer</i> , 2019, 125, 1060-1069.	2.0	28
190	Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression. <i>Journal of Biomolecular Screening</i> , 2006, 11, 678-687.	2.6	25
191	Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. <i>Cell Cycle</i> , 2010, 9, 4183-4189.	1.3	25
192	Loss of <i>Folliculin</i> Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. <i>Stem Cells</i> , 2016, 34, 1068-1082.	1.4	25
193	Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. <i>Journal of Endourology</i> , 2016, 30, 1219-1226.	1.1	25
194	Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. <i>Journal of the American Chemical Society</i> , 2016, 138, 15813-15816.	6.6	25
195	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. <i>Clinical Imaging</i> , 2021, 77, 291-298.	0.8	25
196	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[¹⁸ F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , 2003, 169, 274-275.	0.2	24
197	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. <i>Cancer</i> , 2009, 115, 2247-2251.	2.0	24
198	Discoveries, therapies and opportunities. <i>Nature Reviews Urology</i> , 2014, 11, 614-616.	1.9	24

#	ARTICLE	IF	CITATIONS
199	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20.	0.8	24
200	Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. <i>Nature Communications</i> , 2016, 7, 11588.	5.8	24
201	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. <i>European Urology Oncology</i> , 2022, 5, 176-186.	2.6	24
202	Therapeutic inhibition of HIF-2 α reverses polycythemia and pulmonary hypertension in murine models of human diseases. <i>Blood</i> , 2021, 137, 2509-2519.	0.6	24
203	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. <i>Urology</i> , 1997, 50, 295-301.	0.5	23
204	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2 α induced gene expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2113-2115.	1.0	23
205	The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. <i>European Urology</i> , 2012, 61, 896-898.	0.9	23
206	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumors. <i>Modern Pathology</i> , 2015, 28, 1458-1469.	2.9	23
207	Targeting HIF2 α in Clear-Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 30, 515-517.	7.7	23
208	Multiple painful cutaneous nodules and renal mass. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 683-686.	0.6	22
209	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. <i>Academic Radiology</i> , 2021, 28, 1491-1499.	1.3	22
210	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. <i>Urology</i> , 2021, 149, 89-97.	0.5	22
211	The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. <i>Prostate</i> , 1987, 10, 189-197.	1.2	21
212	Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. <i>Cancer</i> , 1997, 81, 180-186.	2.0	21
213	Familial Renal Cancer: Molecular Genetics and Surgical Management. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-11.	0.3	21
214	Comprehensive genomic and phenotypic characterization of germline <i>FH1</i> deletion in hereditary leiomyomatosis and renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 484-492.	1.5	21
215	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 169, 357-360.	0.2	20
216	Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. <i>Current Urology Reports</i> , 2011, 12, 47-55.	1.0	20

#	ARTICLE	IF	CITATIONS
217	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. <i>Urology</i> , 2019, 124, 91-97.	0.5	20
218	Targeting HIF2 β Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma. <i>Oncotarget</i> , 2012, 3, 1472-1482.	0.8	20
219	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 662-670.	3.6	19
220	Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. <i>ELife</i> , 2019, 8, .	2.8	19
221	A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. <i>Cancer</i> , 1992, 69, 213-218.	2.0	18
222	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. <i>Diagnostic Cytopathology</i> , 2001, 24, 328-332.	0.5	18
223	PARENCHYMAL SPARING SURGERY FOR CENTRAL RENAL TUMORS IN PATIENTS WITH HEREDITARY RENAL CANCERS. <i>Journal of Urology</i> , 2004, 172, 49-53.	0.2	18
224	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. <i>International Urology and Nephrology</i> , 2016, 48, 1817-1821.	0.6	18
225	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. <i>Cell Reports</i> , 2020, 30, 1823-1834.e5.	2.9	18
226	Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management. <i>Journal of Clinical Oncology</i> , 2009, 27, 3731-3733.	0.8	17
227	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. <i>Human Molecular Genetics</i> , 2016, 26, ddw392.	1.4	17
228	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. <i>Nature Communications</i> , 2020, 11, 6314.	5.8	17
229	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	1.2	17
230	Hypoxia-Inducible Factor 2 β Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016, 18, 567-576.	2.3	16
231	Photoinducible Oncometabolite Detection. <i>ChemBioChem</i> , 2019, 20, 360-365.	1.3	16
232	Inhibition of Hypoxia Inducible Factor-2 Transcription: Isolation of Active Modulators from Marine Sponges. <i>Journal of Natural Products</i> , 2012, 75, 1632-1636.	1.5	15
233	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas. <i>JAMA Dermatology</i> , 2015, 151, 1096.	2.0	15
234	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. <i>Urology</i> , 2020, 140, 85-90.	0.5	15

#	ARTICLE	IF	CITATIONS
235	Tonantzitolone cytotoxicity toward renal cancer cells is PKC $\hat{\downarrow}$ - and HSF1-dependent. <i>Oncotarget</i> , 2015, 6, 29963-29974.	0.8	15
236	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. <i>Journal of Urology</i> , 1998, 159, 1148-1151.	0.2	14
237	Targeting VEGF receptors in kidney cancer. <i>Lancet Oncology</i> , The, 2007, 8, 956-957.	5.1	14
238	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindau-Associated Pancreatic Lesions. <i>Journal of the American College of Surgeons</i> , 2014, 218, 997-1003.	0.2	14
239	RCC - advances in targeted therapeutics and genomics. <i>Nature Reviews Urology</i> , 2017, 14, 76-78.	1.9	14
240	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). <i>Genes Chromosomes and Cancer</i> , 2017, 56, 719-729.	1.5	14
241	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. <i>Human Molecular Genetics</i> , 2018, 27, 2712-2724.	1.4	14
242	Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	14
243	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	3.2	13
244	Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. , 1999, 87, 231-237.		12
245	Partial adrenalectomy in patients with multiple adrenal tumors. <i>Current Urology Reports</i> , 2001, 2, 19-23.	1.0	12
246	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1631-1638.	1.8	12
247	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 6539-6548.	0.4	12
248	Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. <i>Methods in Molecular Biology</i> , 2019, 1928, 1-27.	0.4	12
249	Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. <i>Genes</i> , 2021, 12, 261.	1.0	12
250	PULMONARY INFARCTS CAN MIMIC PULMONARY METASTASES FROM RENAL CANCER. <i>Journal of Urology</i> , 1997, 158, 1688-1690.	0.2	11
251	Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 134.e1-134.e8.	0.8	11
252	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	2.0	11

#	ARTICLE	IF	CITATIONS
253	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. <i>Oncotarget</i> , 2017, 8, 17628-17642.	0.8	11
254	Molecular Genetics of Tumor Suppressor Genes in Prostate Carcinoma: the Challenge and the Promise Ahead. <i>Journal of Urology</i> , 1992, 147, 808-809.	0.2	10
255	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. <i>World Journal of Urology</i> , 1996, 14, S2-7.	1.2	10
256	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. <i>Scientific Reports</i> , 2019, 9, 18409.	1.6	10
257	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020, 68, 14-19.	0.8	10
258	Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease. <i>Radiology</i> , 2020, 295, 583-590.	3.6	10
259	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 434-446.	1.5	10
260	Reoperative Partial Nephrectomy—Does Previous Surgical Footprint Impact Outcomes?. <i>Journal of Urology</i> , 2021, 206, 539-547.	0.2	10
261	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
262	Birt-Hogg-Dubouché syndrome initially diagnosed as tuberous sclerosis complex. <i>JAAD Case Reports</i> , 2019, 5, 368-371.	0.4	9
263	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. <i>Genes and Development</i> , 2019, 33, 1641-1656.	2.7	9
264	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. <i>Journal of Urology</i> , 2001, 165, 1623-1624.	0.2	8
265	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 27.e15-27.e21.	0.8	8
266	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. <i>Pharmaceutical Research</i> , 2016, 33, 2459-2469.	1.7	8
267	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 1221-1223.	7.7	8
268	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107308.	1.5	8
269	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
270	Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. <i>International Urology and Nephrology</i> , 2016, 48, 1047-1053.	0.6	7

#	ARTICLE	IF	CITATIONS
271	Vascular Endothelial Growth Factor Receptor–Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e76-e79.	0.8	7
272	Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 344-352.	0.4	7
273	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau–associated Solid Pancreatic Tumors. <i>Radiology</i> , 2019, 290, 116-124.	3.6	7
274	Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. <i>Journal of Biological Chemistry</i> , 2020, 295, 13410-13418.	1.6	7
275	Novel renal medullary carcinoma cell lines, <sc>UOK353</sc> and <sc>UOK360</sc>, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 472-483.	1.5	7
276	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. <i>Electrophoresis</i> , 2000, 21, 2235-2242.	1.3	7
277	The origin, evolution and route to metastasis of clear cell RCC. <i>Nature Reviews Nephrology</i> , 2018, 14, 538-540.	4.1	6
278	Comprehensive characterization of <i>Alu</i>-mediated breakpoints in germline <i>VHL</i> gene deletions and rearrangements in patients from 71 VHL families. <i>Human Mutation</i> , 2021, 42, 520-529.	1.1	6
279	X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. <i>Urology</i> , 2021, 154, 315-319.	0.5	6
280	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2019, 27, 100922.	0.1	5
281	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 931-938.	1.0	5
282	Intravitreal treatment of severe ocular von <sc>Hippel–Lindau</sc> disease using a combination of the <sc>VEGF</sc> inhibitor, ranibizumab and <sc>PDGF</sc> inhibitor, <sc>E10030</sc>: Results from a phase 1/2 clinical trial. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 1048-1059.	1.3	5
283	Renal Cell Carcinoma. <i>Journal of Urology</i> , 1988, 139, 340-341.	0.2	4
284	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 252-255.	0.8	4
285	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. <i>Breast Journal</i> , 1998, 4, 9-12.	0.4	4
286	Kidney cancer: Opportunity for disease specific targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 542.	0.8	4
287	Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. <i>Journal of Cancer</i> , 2011, 2, 271-279.	1.2	4
288	Treating advanced kidney cancer—miles to go before we sleep. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 614-615.	12.5	4

#	ARTICLE	IF	CITATIONS
289	Looking forward, looking back—10 years in urology. <i>Nature Reviews Urology</i> , 2014, 11, 649-655.	1.9	4
290	Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 220-225.	1.8	4
291	The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. <i>Nature Reviews Urology</i> , 2018, 15, 731-732.	1.9	4
292	An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. <i>ACS Chemical Biology</i> , 2020, 15, 856-861.	1.6	4
293	¹⁸ F-fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021, 46, 3301-3308.	1.0	4
294	Treatment of Advanced Renal Cell Carcinoma. , 2012, , 1475-1491.e5.		4
295	Seventh BHD international symposium: recent scientific and clinical advancement. <i>Oncotarget</i> , 2022, 13, 173-181.	0.8	4
296	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. <i>IScience</i> , 2022, 25, 104463.	1.9	4
297	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	4
298	A mouse model of renal cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 802-803.	15.2	3
299	Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2 α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 882-884.	0.9	3
300	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4584-4584.	0.8	3
301	Clinical evaluation of 2-(¹⁸ F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 383-383.	0.8	3
302	Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide—chlorambucil conjugate. <i>Cancer Science</i> , 2022, 113, 2352-2367.	1.7	3
303	Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. <i>Cancer & Metabolism</i> , 2020, 8, 7.	2.4	2
304	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 5375-5384.	1.2	2
305	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. , 2000, 49, 34.		2
306	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235.		2

#	ARTICLE	IF	CITATIONS
307	Defining early-onset kidney cancer: Implications for genetic counseling.. Journal of Clinical Oncology, 2013, 31, 342-342.	0.8	2
308	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	0.5	2
309	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643.	1.7	2
310	Editorial Comment. Urology, 2014, 83, 675.e5.	0.5	1
311	The Metabolic Basis of Kidney Cancer. , 2015, , 89-102.		1
312	Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. Urology Case Reports, 2017, 13, 101-103.	0.1	1
313	Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urology Case Reports, 2017, 13, 107-109.	0.1	1
314	Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. Clinical Genitourinary Cancer, 2019, 17, e482-e484.	0.9	1
315	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
316	Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF α cytotoxicity. , 0, .		1
317	Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. Journal of Clinical Oncology, 2013, 31, 307-307.	0.8	1
318	Aids Case for Diagnosis, 1986 Military Medicine. Military Medicine, 1986, 151, M49-M56.	0.4	0
319	Identification of the genes for kidney cancer. Cancer Biology and Therapy, 2006, 5, 696-699.	1.5	0
320	Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. Urology Case Reports, 2020, 30, 101135.	0.1	0
321	Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. Urology Case Reports, 2021, 37, 101603.	0.1	0
322	Protein expression profiling in the spectrum of renal tumors. FASEB Journal, 2007, 21, A181.	0.2	0
323	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	0.8	0